Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Tema Oncology ETF (CANC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CANC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 33.73% | Avg. Invested days 60 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 20.10 - 29.30 | Updated Date 06/30/2025 |
52 Weeks Range 20.10 - 29.30 | Updated Date 06/30/2025 |
Upturn AI SWOT
Tema Oncology ETF
ETF Overview
Overview
The Tema Oncology ETF (CNCR) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Tema Oncology Index. The fund invests in companies involved in cancer treatment, diagnostics, and research.
Reputation and Reliability
Tema ETFs is a relatively new ETF issuer. Its reputation is still developing, and its reliability is dependent on its performance and adherence to its stated investment objectives.
Management Expertise
Information on the specific management team's experience in oncology and ETF management is limited but can be found on the issuer's website.
Investment Objective
Goal
To provide investment results that correspond to the price and yield performance of the Tema Oncology Index.
Investment Approach and Strategy
Strategy: The ETF tracks the Tema Oncology Index, which focuses on companies involved in the oncology industry.
Composition The ETF holds a basket of stocks involved in cancer treatment, diagnostics, and research.
Market Position
Market Share: Data on CNCR's specific market share within the oncology ETF sector is currently limited due to the specialized and relatively new nature of the fund.
Total Net Assets (AUM): Data for the exact AUM is not available right now. Please check a financial data service such as Bloomberg or Yahoo Finance.
Competitors
Key Competitors
- PJP
- IBB
- XBI
Competitive Landscape
The oncology ETF market is competitive, with CNCR being a relatively new entrant. Advantages may include a more focused approach or a unique weighting methodology. Disadvantages include lower AUM and trading volume compared to established players.
Financial Performance
Historical Performance: Historical performance data is limited due to the ETF's recent inception. Investors should consult financial resources for up-to-date performance figures.
Benchmark Comparison: Performance should be compared to the Tema Oncology Index to assess tracking effectiveness.
Expense Ratio: Expense Ratio for CNCR is 0.75%
Liquidity
Average Trading Volume
The average trading volume for CNCR is relatively low, indicating potentially lower liquidity.
Bid-Ask Spread
The bid-ask spread might be wider due to the lower trading volume, potentially increasing transaction costs.
Market Dynamics
Market Environment Factors
The ETF is influenced by factors such as advancements in cancer treatment, regulatory approvals, healthcare spending, and overall market sentiment towards biotechnology and pharmaceutical companies.
Growth Trajectory
Growth depends on the continued innovation and expansion of the oncology market, including new therapies, diagnostics, and research initiatives. Changes to strategy and holdings are expected to align with advancements in the field.
Moat and Competitive Advantages
Competitive Edge
CNCR's competitive edge lies in its focused exposure to the oncology sector, potentially capturing the growth of companies involved in cancer treatment, diagnostics, and research. The fund tracks a unique index focused on the oncology space. Its targeted approach may offer more precise exposure compared to broader healthcare ETFs. However, it's crucial to consider the risks associated with this specialized focus.
Risk Analysis
Volatility
Volatility can be high due to the inherent risks associated with biotechnology and pharmaceutical companies, including clinical trial failures and regulatory setbacks.
Market Risk
Market risk includes factors affecting the healthcare sector, such as changes in government regulations, patent expirations, and competition from other companies.
Investor Profile
Ideal Investor Profile
The ideal investor is one with a high-risk tolerance and a long-term investment horizon who believes in the growth potential of the oncology sector.
Market Risk
This ETF is suitable for long-term investors seeking targeted exposure to the oncology market, but less suitable for risk-averse investors or active traders due to potential volatility and liquidity concerns.
Summary
The Tema Oncology ETF (CNCR) provides targeted exposure to companies involved in cancer treatment and research. The ETF's performance will depend on the growth of the oncology market. It's most suitable for investors with a high-risk tolerance and long-term investment horizon due to its specialized focus and relatively low AUM. Investors should be mindful of the risks associated with biotechnology and pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tema ETFs Website
- ETF.com
- Yahoo Finance
- Bloomberg
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. Market share data is an estimate based on available AUM and fund data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tema Oncology ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.